Tirtha Chakraborty

Company: Vor Biopharma

Job title: Chief Scientific Officer

Seminars:

Panel Discussion: Overcoming Safety Fears to Build Complex Gene-Edited Therapies 3:30 pm

Comparing traditional gene editing strategies to CRISPR Cas9, Base editing etc How can we achieve a greater repertoire of gene edits in a safe manner? What are the downstream implications for manufacturing if you engage with complex gene editing? Exploring how to improve specificity of endo nucleases whilst balancing cargo sizeRead more

day: Day One Track A PM

Utilizing Gene Editing Technology to Minimize On-target, Off-tumor Toxicity Risk in AML 2:30 pm

Exploring the risks associated with immuno-therapy in AML Next-generation hematopoietic cell transplant Power of genome editing for precision of the drug and the safety of the patientsRead more

day: Day One Track A PM